A greater proportion of tumours were judged suitable for BgRT if delivered after LuPSMA therapy assuming that LuPSMA would eliminate the PSMA avidity of all metastases and that only a single target could be treated within a BTZ. Here, FOLH1 is linked to neoplasm.